Free tool
FAERS Monitor: Gloperba
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210942 or its brand name (Gloperba, Colchicine). Reports on generic versions are filed under their own applications.
Reports
26,563
Serious
21,606
81% of reports
Hospitalization
11,631
Death reported
3,267
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea2,429
- off label use2,256
- drug ineffective2,052
- nausea1,809
- fatigue1,643
- dyspnoea1,371
- arthralgia1,356
- acute kidney injury1,318
- headache1,279
- vomiting1,240
- toxicity to various agents1,230
- pain1,135
- drug interaction1,119
- gout1,109
- rash993
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 223 |
| 2005 | 284 |
| 2006 | 236 |
| 2007 | 232 |
| 2008 | 253 |
| 2009 | 419 |
| 2010 | 536 |
| 2011 | 816 |
| 2012 | 695 |
| 2013 | 564 |
| 2014 | 625 |
| 2015 | 970 |
| 2016 | 1,281 |
| 2017 | 1,272 |
| 2018 | 1,594 |
| 2019 | 2,117 |
| 2020 | 2,139 |
| 2021 | 1,802 |
| 2022 | 1,952 |
| 2023 | 2,096 |
| 2024 | 2,220 |
| 2025 | 2,493 |
| 2026 | 1,743 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,027,596 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| goutSignal | 1,109 | 52.1 | 49.1 | 52,132 |
| acute kidney injurySignal | 1,318 | 6.9 | 6.5 | 6,596 |
| toxicity to various agentsSignal | 1,230 | 5.8 | 5.5 | 4,897 |
| drug interactionSignal | 1,119 | 5.6 | 5.3 | 4,245 |
| diarrhoeaSignal | 2,429 | 3.0 | 2.9 | 3,298 |
| arthralgiaSignal | 1,356 | 2.6 | 2.5 | 1,341 |
| vomitingSignal | 1,240 | 2.1 | 2.0 | 719 |
| off label useSignal | 2,256 | 2.0 | 2.0 | 1,249 |
| dyspnoea | 1,371 | 1.9 | 1.8 | 619 |
| nausea | 1,809 | 1.8 | 1.7 | 681 |
| rash | 993 | 1.8 | 1.7 | 363 |
| fatigue | 1,643 | 1.7 | 1.6 | 460 |
| headache | 1,279 | 1.6 | 1.5 | 309 |
| pain | 1,135 | 1.5 | 1.4 | 171 |
| drug ineffective | 2,052 | 1.2 | 1.2 | 96 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.